The global market for artificial intelligence (AI) in drug discovery is witnessing remarkable growth, primarily fueled by the pressing need for more efficient drug discovery procedures, the escalating integration of AI and machine learning technologies within the pharmaceutical sector, and the surging demand for personalized medicine. AI stands poised to transform the drug discovery landscape by expediting the identification of new drug candidates, forecasting interactions between drugs and targets, enhancing the optimization of lead compounds, and diminishing the time and expenses linked with conventional drug discovery methodologies. The market is witnessing rapid advancements, fueling the growth of companies operating in this sector. These developments are enabling companies to improve their drug discovery processes, leading to the development of more effective and targeted therapies. AI and machine learning algorithms analyze large datasets, identify potential drug candidates, predict their properties, and optimize lead compounds. This has significantly reduced the time and cost of traditional drug discovery methods, driving the growth of companies offering AI solutions.
The Global Artificial Intelligence (AI) in Drug Discovery Market size was valued at USD 932.24 billion in 2023 and is projected to reach USD 1,409.14 billion by 2031, with a CAGR of 5.30% during the forecast period of 2024 to 2031.
Below are the Top Five Facial Cleanser Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
NVIDIA Corporation
|
NVIDIA Corporation, known for its advanced GPU technologies, is a key player in the market. NVIDIA's GPUs are widely used in AI and machine learning applications, including drug discovery, due to their ability to process large amounts of data in parallel. NVIDIA's AI platforms, such as the NVIDIA DGX systems and NVIDIA Clara Discovery, are specifically designed to accelerate drug discovery workflows. These platforms enable researchers to analyze complex biological data, predict molecular structures, and simulate drug interactions more efficiently and accurately. NVIDIA's partnerships with pharmaceutical companies and research institutions have further strengthened its position in the market, as these collaborations have led to the development of innovative AI-based solutions for drug discovery. Overall, NVIDIA's advanced GPU technologies and AI platforms are driving significant advancements in drug discovery, making it a key player in the global market.
|
|
North America, Middle East and Africa, Europe, South America, and Asia-Pacific
|
In March 2022, NVIDIA Corporation launched Clara Holoscan MGX to develop and deploy real-time AI applications. Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, and long-term software support to accelerate innovation in the medical device industry. This will help the company improve AI performance in the health sector for surgery, diagnostics, and drug discovery.
|
|
2.
|
Microsoft
|
Microsoft Corporation, a leading technology company, plays a significant role in the market. Microsoft offers a range of AI tools and services, including Azure Machine Learning, which enables researchers to build, train, and deploy machine learning models for drug discovery applications. Microsoft's AI capabilities are being utilized to analyze vast amounts of biomedical data, such as genomic and proteomic data, to identify potential drug candidates and predict their efficacy. Microsoft's partnerships with pharmaceutical companies and research institutions are also driving innovation in drug discovery. These collaborations are leading to the development of new AI-driven solutions that are helping to accelerate the drug discovery process and bring new therapies to market faster. Overall, Microsoft's AI technologies are crucial in advancing drug discovery efforts, making it a key player in the global market.
|
|
North America, Middle East and Africa, Europe, South America, and Asia-Pacific
|
In October 2019, Microsoft and Novartis AG announced a collaboration to transform medicine with artificial intelligence. The company announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aimed to bolster AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide. This has helped the company to expand its research in drug discovery.
|
|
3.
|
IBM Corp
|
IBM Corporation, a global technology company, is a major player in the market. IBM offers Watson for Drug Discovery, a powerful AI platform that leverages natural language processing and machine learning to analyze vast amounts of scientific literature, clinical trial data, and other sources to identify potential drug candidates. IBM's AI solutions are helping pharmaceutical companies and research institutions accelerate the drug discovery process by predicting drug-target interactions, optimizing lead compounds, and reducing the time and cost associated with traditional drug discovery methods. IBM's partnerships with leading healthcare organizations and research institutions further strengthen its position in the market, as these collaborations drive the development of innovative AI-based solutions for drug discovery. Overall, IBM's AI technologies are significantly advancing drug discovery efforts, making it a key player in the global market.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In July 2019, at the 18th European Conference on Computational Biology (ECCB) and the 27th Conference on Intelligent Systems for Molecular Biology (ISMB) in Basel, Switzerland, IBM had presented significant, novel research that led to the implementation of three machine learning solutions aimed at accelerating and guiding cancer research. The company has built machine learning approaches that can help accelerate understanding of the leading drivers and molecular mechanisms of these complex diseases and the differences in tumor composition occurring across various cancer types. This has helped the company show its progress in drug discovery.
|
|
4.
|
Schrödinger, Inc.
|
Schrödinger, Inc. is a leading provider of computational chemistry software and services specializing in applying physics-based simulations to drug discovery. The company offers a range of software solutions that leverage artificial intelligence (AI) and machine learning algorithms to accelerate the drug discovery process. Schrödinger's software allows researchers to simulate and analyze molecular structures, predict how drugs will interact with biological targets, and optimize lead compounds for efficacy and safety. The company's AI-driven approach has been instrumental in helping pharmaceutical companies and research institutions identify novel drug candidates and bring them to market more quickly and cost-effectively. Schrödinger's innovative technologies and a strong focus on drug discovery have positioned it as a key player in the global AI drug discovery market.
|
|
North America, Europe, South America, and Asia-Pacific
|
In June 2022, Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505. Schrödinger expects to initiate a Phase 1 clinical trial of SGR-1505 in patients with relapsed or refractory B-cell lymphoma in the second half of 2022. This has helped the company to expand its product portfolio.
|
|
5.
|
BERG LLC
|
Berg LLC is a biopharmaceutical company that utilizes AI and machine learning to discover and develop new therapies for various diseases. The company's Interrogative Biology platform integrates patient biology and artificial intelligence to identify biomarkers and potential drug targets. Berg's AI-driven approach enables the rapid analysis of complex biological data and the discovery of novel drug candidates. The company strongly focuses on precision medicine, aiming to develop personalized therapies that target the underlying mechanisms of disease. Berg's innovative technologies and unique approach to drug discovery have positioned it as a key player in the global market.
|
|
North America, South America
|
In July 2021, BERG LLC, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments and diagnostics, announced the publication of a new study entitled “Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia” in Scientific Reports. As part of the study, BERG evaluated over 750 patients at geographically diverse medical centers in the U.S. and Canada, where they applied the biomarker panel, comprised of filamin-A (FLNA), age, and prostate volume, to predict and stratify men with BPH from those with PCa. BERG’s Interrogative Biology platform has enabled the develop the first AI blood-based biomarker for disease diagnosis in managing both prostate cancer and BPH diagnosis. This has helped the company to show its success in studying AI.
|
Conclusion
The global artificial intelligence (AI) in drug discovery market is experiencing significant growth, driven by the increasing need for more efficient drug discovery processes, the rising adoption of AI and machine learning technologies in the pharmaceutical industry, and the growing demand for personalized medicine. Companies such as IBM, Microsoft, NVIDIA, Schrödinger, and Berg play a crucial role in driving this growth through innovative AI solutions and partnerships with pharmaceutical companies and research institutions. These companies are helping to accelerate the drug discovery process, identify novel drug candidates, and bring new therapies to market faster, ultimately benefiting patients worldwide. As the adoption of AI in drug discovery continues to increase, there is ample opportunity for further growth and innovation in this dynamic market.
